Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer.

Chongqing, Tan; Sini, Li; Xiaohui, Zeng; Liubao, Peng; Ye, Peng; Shuxia, Qin; Liting, Wang; Meiyu, Wu; Xiaomin, Wan

Chongqing, Tan; Sini, Li; Xiaohui, Zeng; Liubao, Peng; Ye, Peng; Shuxia, Qin; Liting, Wang; Meiyu, Wu; Xiaomin, Wan.

Affiliation

Chongqing T; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Sini L; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Xiaohui Z; School of Health and Related Research, Faculty of Medicine, Dentistry and Health, University of Sheffield, Sheffield, United Kingdom.
Liubao P; PET Imaging Center, The Second Xiangya Hospital, Central South University, Changsha, China.
Ye P; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Shuxia Q; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Liting W; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.
Meiyu W; Institute of Clinical Pharmacy, Central South University, Changsha, China.
Xiaomin W; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, China.

Front Pharmacol ; 12: 802942, 2021.

Article in En | MEDLINE | ID: mdl-34970153

Key words

colorectal neoplasms; cost-effectiveness; immunotherapy; microsatellite-instability-high/mismatch repair-deficient; pembrolizumab

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Guideline / Health_economic_evaluation Aspects: Patient_preference Language: En Journal: Front Pharmacol Year: 2021 Document type: Article Affiliation country: China Country of publication: Switzerland

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google